351,600 Shares in Gossamer Bio, Inc. $GOSS Acquired by OMERS ADMINISTRATION Corp

Key Points

• OMERS ADMINISTRATION Corp acquired a new stake in Gossamer Bio, purchasing 351,600 shares valued at approximately $387,000, representing about 0.15% of the company.
• Gossamer Bio recently reported a quarterly loss of ($0.17) earnings per share, slightly beating the consensus estimate of ($0.18), with a revenue of $11.49 million for the quarter.
• Several institutional investors have increased their positions in Gossamer Bio, with Octagon Capital Advisors LP raising its holdings by 99.7%, now owning 18.35 million shares.

OMERS ADMINISTRATION Corp purchased a new position in Gossamer Bio, Inc. (NASDAQ:GOSS - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 351,600 shares of the company's stock, valued at approximately $387,000. OMERS ADMINISTRATION Corp owned 0.15% of Gossamer Bio as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also modified their holdings of GOSS. Graham Capital Management L.P. purchased a new stake in shares of Gossamer Bio during the 4th quarter worth approximately $32,000. Virtu Financial LLC acquired a new position in Gossamer Bio in the first quarter worth $38,000. Fullcircle Wealth LLC bought a new stake in shares of Gossamer Bio during the fourth quarter valued at about $43,000. Invesco Ltd. purchased a new position in Gossamer Bio in the 1st quarter worth about $48,000. Finally, Velan Capital Investment Management LP acquired a new stake in Gossamer Bio in the 4th quarter worth approximately $68,000. Institutional investors and hedge funds own 81.23% of the company's stock.

Analysts Set New Price Targets

GOSS has been the topic of several analyst reports. Wall Street Zen lowered Gossamer Bio from a "hold" rating to a "sell" rating in a research note on Saturday, August 9th. Scotiabank started coverage on Gossamer Bio in a research report on Monday, July 14th. They issued a "sector outperform" rating and a $11.00 price target for the company. Wedbush upped their target price on Gossamer Bio from $4.00 to $5.00 and gave the stock an "outperform" rating in a report on Wednesday, August 6th. Finally, The Goldman Sachs Group raised their target price on Gossamer Bio from $7.00 to $8.00 and gave the stock a "buy" rating in a report on Friday, May 16th. Four research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $8.50.

Gossamer Bio Stock Down 8.7%

NASDAQ:GOSS traded down $0.26 during midday trading on Monday, hitting $2.69. 4,275,286 shares of the company were exchanged, compared to its average volume of 2,108,193. The company has a current ratio of 4.40, a quick ratio of 4.40 and a debt-to-equity ratio of 6.70. The company has a market capitalization of $610.52 million, a PE ratio of -4.33 and a beta of 1.95. Gossamer Bio, Inc. has a fifty-two week low of $0.66 and a fifty-two week high of $3.00. The company has a fifty day simple moving average of $1.90 and a 200 day simple moving average of $1.40.

Gossamer Bio (NASDAQ:GOSS - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.01. Gossamer Bio had a negative net margin of 344.81% and a negative return on equity of 1,774.72%. The firm had revenue of $11.49 million during the quarter, compared to analyst estimates of $4.12 million. As a group, equities analysts anticipate that Gossamer Bio, Inc. will post -0.28 earnings per share for the current fiscal year.

Gossamer Bio Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.